- Home
- RYI vs PLRX Comparison
RYI vs PLRX Comparison
Compare RYI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYI
- PLRX
- Stock Information
- Founded
- RYI 1842
- PLRX 2015
- Country
- RYI United States
- PLRX United States
- Employees
- RYI N/A
- PLRX 166
- Industry
- RYI Metal Fabrications
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RYI Industrials
- PLRX Health Care
- Exchange
- RYI Nasdaq
- PLRX Nasdaq
- Market Cap
- RYI 661.1M
- PLRX 682.2M
- IPO Year
- RYI N/A
- PLRX 2020
- Fundamental
- Price
- RYI $20.75
- PLRX $11.21
- Analyst Decision
- RYI Hold
- PLRX Strong Buy
- Analyst Count
- RYI 1
- PLRX 7
- Target Price
- RYI $28.00
- PLRX $40.50
- AVG Volume (30 Days)
- RYI 270.1K
- PLRX 577.5K
- Earning Date
- RYI 02-19-2025
- PLRX 02-26-2025
- Dividend Yield
- RYI 3.62%
- PLRX N/A
- EPS Growth
- RYI N/A
- PLRX N/A
- EPS
- RYI 0.64
- PLRX N/A
- Revenue
- RYI $4,703,700,000.00
- PLRX N/A
- Revenue This Year
- RYI N/A
- PLRX N/A
- Revenue Next Year
- RYI $1.76
- PLRX N/A
- P/E Ratio
- RYI $32.60
- PLRX N/A
- Revenue Growth
- RYI N/A
- PLRX N/A
- 52 Week Low
- RYI $17.18
- PLRX $10.22
- 52 Week High
- RYI $36.15
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- RYI 54.59
- PLRX 37.19
- Support Level
- RYI $17.18
- PLRX $11.02
- Resistance Level
- RYI $18.73
- PLRX $12.70
- Average True Range (ATR)
- RYI 0.75
- PLRX 0.80
- MACD
- RYI 0.47
- PLRX -0.18
- Stochastic Oscillator
- RYI 89.92
- PLRX 8.21
About RYI Ryerson Holding Corporation
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority is from the United States.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.